Skip to main content
. 2021 Jul 1;2021:9965099. doi: 10.1155/2021/9965099

Figure 5.

Figure 5

hsa-miR-329-3p inhibits HCC tumor growth by increasing the T cell response by controlling PD-L1 expression in the KDM1A/MEF2D pathway. (a–c) The volume and weight of subcutaneous xenograft tumors of H22 cells with or without miR-329-3p isolated from mice. The volume was measured every week starting at 2 weeks after injection. The weight was measured at 6 weeks after injection. (d) mRNA/miRNA expression of KDM1A, PD-L1, and miR-329-3p in xenograft tumors at 6 weeks after injection. (e) Top: proteins immunoprecipitated with anti-K267me were analyzed using anti-MEF2D. Bottom: protein expression in whole cell lysates from xenograft tumors at 6 weeks after injection. (f) FACS results of PD-L1 expression in xenograft tumors at 6 weeks after injection. The data are presented as the means ± SD. n = 6 experiments in (a–f). ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.01.